NeoImmuneTech, Inc. (950220.KQ) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	95.8M	94.8M	170.4M	—	—
Cost of Revenue	(135.00)	—	—	—	—
Gross Profit	95.5M	94.8M	170.4M	—	—
Operating Expenses
R&D Expense	(436.00)	17.2B	—	—	—
SG&A Expense	—	15.0B	37.5B	52.6B	37.0B
General & Admin Expense	—	1.5B	19.0B	27.1B	4.8B
Selling & Marketing Expense	—	13.5B	18.4B	25.5B	32.2B
Other Expenses	25.6B	(6.9B)	—	3.0B	21.2B
Total Operating Expenses	25.6B	25.3B	37.5B	55.6B	58.2B
Cost and Expenses	25.6B	25.3B	37.5B	55.6B	58.2B
Operating Income (EBIT)	(25.2B)	(25.2B)	(37.3B)	(55.6B)	(58.2B)
Non-Operating
Interest Income	—	2.1B	1.8M	2.9B	1.2B
Interest Expense	(315.00)	8.8B	726.0K	225.3M	261.4M
Net Interest Income	315.00	(6.7B)	1.1M	2.7B	892.6M
Other Non-Op Income/Expense	(7.0B)	(7.0B)	(3.6B)	2.3B	(2.1B)
Non-Operating Income (excl Interest)	1.0K	—	3.7B	(2.3B)	1.8B
EBT (Pre-Tax Income)	(32.2B)	(32.2B)	(40.9B)	(53.3B)	(60.3B)
Income Tax Expense	(9.7M)	(11.4M)	12.8M	101.3M	116.4M
Bottom Line
Net Income	(32.0B)	(32.2B)	(40.9B)	(53.4B)	(60.4B)
Earnings from Cont. Ops	(32.0B)	(32.2B)	(40.9B)	(53.4B)	(60.4B)
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	(32.0B)	(32.2B)	(40.9B)	(53.4B)	(60.4B)
Per Share
Basic EPS	(₩1,124)	(₩196)	(₩2,073)	(₩540)	(₩612)
Diluted EPS	(₩1,124)	(₩196)	(₩2,073)	(₩540)	(₩612)
Revenue Per Share	₩1	₩1	₩9	₩0	₩0
Shares
Basic Shares Outstanding	164.4M	164.4M	19.7M	98.8M	98.8M
Diluted Shares Outstanding	164.4M	164.4M	19.7M	98.8M	98.8M
Profitability Metrics
EBITDA	(28.1B)	(22.8B)	(36.2M)	(50.1B)	(57.2B)
D&A	1.8B	2.5B	4.0M	3.2B	2.8B
EBIT	(25.7B)	(25.2B)	(40.1M)	(53.3B)	(60.0B)

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Dec 1, 2025